US20120288505A1 - Gene delivery - Google Patents
Gene delivery Download PDFInfo
- Publication number
- US20120288505A1 US20120288505A1 US13/535,267 US201213535267A US2012288505A1 US 20120288505 A1 US20120288505 A1 US 20120288505A1 US 201213535267 A US201213535267 A US 201213535267A US 2012288505 A1 US2012288505 A1 US 2012288505A1
- Authority
- US
- United States
- Prior art keywords
- cells
- magnetic
- magnetic means
- particles
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
Definitions
- the present invention relates to methods for the delivery of therapeutic agents to target cells.
- Cystic fibrosis causes the body to produce thick secretions that affect the lungs and digestive tract.
- cystic fibrosis undergoes an operation within the first few days of life due to a bowel obstruction.
- Children and adults suffer from repeated chest infections and problems with pancreas function. The latter complication makes it difficult for cystic fibrosis sufferers to digest food. This can lead to malnutrition, poor growth, physical weakness and delayed puberty.
- insulin production can become deficient due to increasing pancreatic disease thus resulting in diabetes.
- Cystic fibrosis can also cause blockages of liver ducts. This occurs in approximately 8% of sufferers however the health risk is so severe that liver transplants are necessary. While the disease has serious effects on the gut, pancreas, liver and reproductive tract the effect it has on the lungs are the most severe. Repeated cycles of infection lead to continuous inflammation and damage to the lungs which ultimately leads to respiratory failure and death.
- Cystic fibrosis is a genetic disease caused by a mutation within a single gene, CFTR (Cystic Fibrosis Trans-membrane Conductance Regulator).
- CFTR Cystic Fibrosis Trans-membrane Conductance Regulator
- Gene therapy has been tested on humans using viruses and liposomes as transfection vectors.
- Recombinant viruses used for gene transfer need to be able to infect both dividing and non-dividing cells, integrate into the host genome and give long term gene expression.
- the viral vectors tested so far adenovirus, retrovirus, adeno-associated virus and sendai virus
- Viral vectors used as gene delivery systems also have potential safety issues and are ineffective long term due to a triggering of the immune response. Similar transfection problems apply to a wide variety of genetic diseases.
- Non-viral agents are non-infectious, relatively non-immunogenic, have low toxicity, can carry larger DNA plasmids and can be produced cheaply on a large scale.
- One type of agent is DNA-coated magnetic particles.
- a method of delivery of a therapeutic agent to a target cell comprising targeting particles comprising the therapeutic agent to the cell using magnetic means to apply a magnetic force to the particles so as to tend to move the particles towards or away from the magnetic means and at the same time moving the magnetic means.
- the magnetic means are used to apply a magnetic force to the particles so as to tend to move the particles in a first direction towards or away from the magnetic means and at the same time moving the magnetic means relative to the particles in a second direction at an angle to the first direction.
- the movement of the magnetic means in a second direction is generally at a non-zero angle to the first direction, for example at an angle between 0 and 180°, such as at an angle of between 0 and 90°, to the first direction.
- the movement of the magnetic means in a second direction is an oscillating movement.
- the oscillation frequency at which the magnet(s) is driven will usually be varied and will generally be in the range of 0 up to 100 Hz although values outside this range may be used.
- the movement of the magnetic means in a second direction is substantially perpendicular to the first direction in which the particles tend to move.
- the magnetic force applied to the particles so as to move the particles towards or away from the magnetic means may be described as a translational force.
- the translational force is produced by a magnetic field with a gradient.
- the direction of the translational force is towards the magnet.
- the magnetic means is a magnet or array of magnets.
- the magnet may be an electromagnet.
- the particles may be attracted to, or repelled from, the magnetic means.
- the particles are attracted to the magnetic means.
- the particle is a magnetic particle.
- the particle is made from a magnetizable material.
- the magnetizable particle may be inherently magnetic or may be one which reacts in a magnetic field.
- any magnetic material may be used, however, by the term magnetic we mean, for example, a material which is paramagnetic superparamagnetic, ferromagnetic, and/or antiferromagnetic, examples of which include elemental iron, chromium manganese, cobalt, nickel, or a compound thereof.
- the iron compound may be an iron salt which may be selected from the group which includes magnetite (Fe 3 O 4 ), maghemite ( ⁇ Fe 2 O 3 ) and greigite (Fe 3 S 4 ), or any combination thereof.
- the chromium compound may be chromium dioxide.
- the particles may be provided within the pores of a polymer.
- the particles may comprise a magnetic core with a biocompatible coating.
- the biocompatible coating may comprise a polymer, e.g. dextran, polyvinyl alcohol (PVA), polyethylenimine (PEI) or silica.
- the particles have a mean size of between 10 ⁇ m and 5 nm, for example between 1 ⁇ m and 10 nm.
- the particles are nanoparticles.
- ⁇ is the torque
- ⁇ is the magnetic moment
- B is the magnetic flux density
- ⁇ is the angle between the applied field and the particle's magnetization vector.
- the cell may be a bacterial cell, plant cell or animal cell.
- the animal cell may be a mammalian cell, for example a human cell.
- the cell may be a lung cell, kidney cell, nerve cell, mesenchymal cell, muscle cell (cardiomyocyte), liver cell, red or white blood cell (e.g. erythrocyte, lymphocyte, monocyte, macrophage, leukocyte), pancreatic ⁇ cell; epithelial cell (e.g. lung, gastric), endothelial cell, bone cell, skin cell, gastrointestinal cell, bladder cell, reproductive cell (sperm or egg cell), cells of the uterus, prostate or endocrine gland (e.g. pituitary); embryonic stem (ES) cells; embryonal germ (EG) cells, tumor cell, cancer cell.
- erythrocyte lymphocyte
- monocyte monocyte
- macrophage leukocyte
- pancreatic ⁇ cell e.g. erythrocyte, lymphocyte, monocyte, macrophage, leukocyte
- pancreatic ⁇ cell e.g. erythrocyte, lymphocyte, monocyte, macrophage, leukocyte
- the method of the invention may be an ex vivo or in vivo method. Preferably the method is carried out in vivo.
- the method described herein has application in the treatment of a wide range of disorders including.
- the method has application as a method for the treatment or prevention of clinical disorders and diseases.
- the therapeutic agent may be a pharmaceutical, nutraceutical or agrochemical agent.
- the pharmaceutical agent may include DNA, RNA, interfering RNA (RNAi), a peptide, polypeptide, an antibody (e.g. antibody fragment such as a single chain antibody fragment), an aptamer, a small molecule.
- Small molecules may include, but are not limited to, peptides, peptidomimetics (e.g., peptoids), amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including hetero-organic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.
- peptides e.g., peptoids
- amino acids amino acid analogs
- polynucleotides polynucleotide analogs
- nucleotides nucleotide analogs
- the therapeutic agent is DNA.
- the therapeutic agent is the gene encoding the Cystic Fibrosis Trans-membrane Conductance Regulator.
- a further aspect of the invention provides the use of moveable magnetic means in the manufacture of a system for targeting particles comprising a therapeutic agent to a target cell.
- the magnetic means are in motion, preferably still in constant motion.
- the magnetic means are used to apply a magnetic force to the particles so as to tend to move the particles towards or away from the magnetic means and at the same time moving the magnetic means.
- the magnetic means are used to apply a magnetic force to the particles so as to tend to move the particles in a first direction towards or away from the magnetic means and at the same time moving the magnetic means relative to the particles in a second direction at an angle to the first direction.
- the magnetic means may be moved external to the body.
- the movement of the magnetic means may be controlled by a motor or a magnet.
- the movement of the magnetic means may be remotely controlled.
- FIG. 1 is a schematic representation of the magnet array drive system and sample holder for in vitro cell culture and Air/Liquid Interface (tissue) studies;
- FIG. 2 shows GFP expression in HEK293T cells transfected with 150 nm magnetic nanoparticles coated with pEGFPC 1 DNA in response to magnetic field;
- FIG. 3 is a histogram showing luciferase activity in HEK293 T cells transfected with 150 nm magnetic nanoparticles coated with pCIKLux luciferase reporter;
- the reporter genes Green Fluorescent Protein (GFP) and luciferase were attached to commercially available magnetic nanoparticles.
- the particles generally consisted of a magnetic core (magnetite—Fe 3 O 4 and/or its oxidation product maghemite— ⁇ Fe 2 O 3 ) with a polymer coating, such as dextran, PVA or silica, and ranged in size from ⁇ 10 nm to ⁇ 1 ⁇ m.
- Magnetite is a naturally occurring iron oxide and is found in many organs in the human body. In addition magnetite is FDA-approved for MRI contrast enhancement and thus is suitable for clinical trials.
- Magnetic nano-particles coated with 1800 branched polyethyleneimine (PEI) were incubated with DNA in order to bind the reporter genes to the particles.
- the gene/particle complex was then introduced into mono-layer cultures of HEK293T kidney cells within the incubator. Culture dishes were positioned on a custom-built holder above the magnet array, housed within the incubator.
- the reporter gene/particle complex is targeted to cells via a high gradient rare earth (NdFeb) magnet which are focused over the target site. These magnets produce a translational force on the particles due to the high field strength/gradient product according to the equation:
- F mag ( x 2 - x 1 ) ⁇ V ⁇ ⁇ 1 ⁇ o ⁇ B ⁇ ( ⁇ B )
- x 2 is the volume magnetic susceptibility of the magnetic particle
- x 1 is the volume magnetic susceptibility of the surrounding medium
- ⁇ o is the magnetic permeability of free space
- B is the magnetic flux density in Telsa (T) (Pankhurst et al. 2003). This translational force ‘pulls’ the particles towards the magnet.
- the particles are delivered using a high precision oscillating horizontal drive system which is controlled by a computer and custom designed control software.
- the amplitude of the array's drive system can vary between a few nanometers to millimeters and the frequency can vary from static up to 100's of Hz depending upon the parameters for the target.
- HEK293T cells were seeded in 96 well plates at 5 ⁇ 10 3 cells/well.
- the cells were transfected with 5 ug/well of 150 nm dextran/magnetite composite nanoparticles coated with PEI, loaded with pCIKlux DNA (binding capacity approx 0.2 ug DNA/ug particles).
- the cells were exposed to magnetic fields as shown for 24 hr post transfection, using a stack of 3 ⁇ NdFeB 4 mm magnets per well.
- the cells exposed to moving field were exposed for 2 hrs at 2 Hz using a 200 ⁇ m displacement and then the magnets left in place for 22 hrs in static position.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 11/912,198, filed Jun. 12, 2008, which is the US national phase entry of International Patent Application No. PCT/GB2006/001477, filed Apr. 21, 2006, which claims priority to UK Patent Application No. 0508110.4, filed Apr. 22, 2005.
- The present invention relates to methods for the delivery of therapeutic agents to target cells.
- Cystic fibrosis causes the body to produce thick secretions that affect the lungs and digestive tract. One in every ten babies born with cystic fibrosis undergoes an operation within the first few days of life due to a bowel obstruction. Children and adults suffer from repeated chest infections and problems with pancreas function. The latter complication makes it difficult for cystic fibrosis sufferers to digest food. This can lead to malnutrition, poor growth, physical weakness and delayed puberty. In older patients insulin production can become deficient due to increasing pancreatic disease thus resulting in diabetes. Cystic fibrosis can also cause blockages of liver ducts. This occurs in approximately 8% of sufferers however the health risk is so severe that liver transplants are necessary. While the disease has serious effects on the gut, pancreas, liver and reproductive tract the effect it has on the lungs are the most severe. Repeated cycles of infection lead to continuous inflammation and damage to the lungs which ultimately leads to respiratory failure and death.
- Cystic fibrosis is a genetic disease caused by a mutation within a single gene, CFTR (Cystic Fibrosis Trans-membrane Conductance Regulator). Thus by treating patients using gene therapy it is possible to treat the underlying cause of the disease and not the symptoms. Introduction of CFTR has been shown to correct the cystic fibrosis defect in vitro. Gene therapy has been tested on humans using viruses and liposomes as transfection vectors. Recombinant viruses used for gene transfer need to be able to infect both dividing and non-dividing cells, integrate into the host genome and give long term gene expression. Of all of the viral vectors tested so far (adenovirus, retrovirus, adeno-associated virus and sendai virus) non have all of these features. Viral vectors used as gene delivery systems also have potential safety issues and are ineffective long term due to a triggering of the immune response. Similar transfection problems apply to a wide variety of genetic diseases.
- The present invention addresses the need for a non-viral gene transfection agent which mitigates the disadvantages associated with recombinant viral vectors. Non-viral agents are non-infectious, relatively non-immunogenic, have low toxicity, can carry larger DNA plasmids and can be produced cheaply on a large scale. One type of agent is DNA-coated magnetic particles.
- Current magnetic based transfection systems have a low efficiency of transformation. The present inventors have developed a magnetic particle based delivery system which has surprisingly been shown to have a transformation efficiency 10 times greater than the current systems based on initial in vitro studies.
- According to a first aspect of the invention there is provided a method of delivery of a therapeutic agent to a target cell the method comprising targeting particles comprising the therapeutic agent to the cell using magnetic means to apply a magnetic force to the particles so as to tend to move the particles towards or away from the magnetic means and at the same time moving the magnetic means.
- In a preferred aspect of the invention the magnetic means are used to apply a magnetic force to the particles so as to tend to move the particles in a first direction towards or away from the magnetic means and at the same time moving the magnetic means relative to the particles in a second direction at an angle to the first direction.
- The movement of the magnetic means in a second direction is generally at a non-zero angle to the first direction, for example at an angle between 0 and 180°, such as at an angle of between 0 and 90°, to the first direction.
- Preferably the movement of the magnetic means in a second direction is an oscillating movement. The oscillation frequency at which the magnet(s) is driven will usually be varied and will generally be in the range of 0 up to 100 Hz although values outside this range may be used.
- In a preferred aspect of the invention the movement of the magnetic means in a second direction is substantially perpendicular to the first direction in which the particles tend to move.
- The magnetic force applied to the particles so as to move the particles towards or away from the magnetic means may be described as a translational force. The translational force is produced by a magnetic field with a gradient. Preferably the direction of the translational force is towards the magnet.
- In a preferred aspect of the invention the magnetic means is a magnet or array of magnets. The magnet may be an electromagnet.
- The particles may be attracted to, or repelled from, the magnetic means. Preferably the particles are attracted to the magnetic means.
- In a further preferred aspect of the invention the particle is a magnetic particle. Preferably the particle is made from a magnetizable material. The magnetizable particle may be inherently magnetic or may be one which reacts in a magnetic field.
- Generally, any magnetic material may be used, however, by the term magnetic we mean, for example, a material which is paramagnetic superparamagnetic, ferromagnetic, and/or antiferromagnetic, examples of which include elemental iron, chromium manganese, cobalt, nickel, or a compound thereof. The iron compound may be an iron salt which may be selected from the group which includes magnetite (Fe3O4), maghemite (γFe2O3) and greigite (Fe3S4), or any combination thereof. The chromium compound may be chromium dioxide.
- The particles may be provided within the pores of a polymer. Alternatively, the particles may comprise a magnetic core with a biocompatible coating. The biocompatible coating may comprise a polymer, e.g. dextran, polyvinyl alcohol (PVA), polyethylenimine (PEI) or silica.
- In a further preferred aspect of the invention the particles have a mean size of between 10 μm and 5 nm, for example between 1 μm and 10 nm.
- Preferably the particles are nanoparticles.
- Larger, magnetically blocked particles (>30 nm for magnetite) will experience a torque in the oscillating field as the field vector changes its angle with respect to the magnetization vector of the particles according to the equation:
-
τ=μB sin θ - where τ is the torque, μ is the magnetic moment, B is the magnetic flux density and θ is the angle between the applied field and the particle's magnetization vector. This twisting, wedging and pulling enhances the movement of the particle/therapeutic agent complex resulting in the improved uptake in the cells.
- In the method of the invention, the cell may be a bacterial cell, plant cell or animal cell. The animal cell may be a mammalian cell, for example a human cell.
- In the method of the invention, the cell may be a lung cell, kidney cell, nerve cell, mesenchymal cell, muscle cell (cardiomyocyte), liver cell, red or white blood cell (e.g. erythrocyte, lymphocyte, monocyte, macrophage, leukocyte), pancreatic β cell; epithelial cell (e.g. lung, gastric), endothelial cell, bone cell, skin cell, gastrointestinal cell, bladder cell, reproductive cell (sperm or egg cell), cells of the uterus, prostate or endocrine gland (e.g. pituitary); embryonic stem (ES) cells; embryonal germ (EG) cells, tumor cell, cancer cell.
- The method of the invention may be an ex vivo or in vivo method. Preferably the method is carried out in vivo.
- The method described herein has application in the treatment of a wide range of disorders including. Thus the method has application as a method for the treatment or prevention of clinical disorders and diseases.
- In the method of the invention the therapeutic agent may be a pharmaceutical, nutraceutical or agrochemical agent. The pharmaceutical agent may include DNA, RNA, interfering RNA (RNAi), a peptide, polypeptide, an antibody (e.g. antibody fragment such as a single chain antibody fragment), an aptamer, a small molecule. Small molecules may include, but are not limited to, peptides, peptidomimetics (e.g., peptoids), amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including hetero-organic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.
- In a preferred method of the invention the therapeutic agent is DNA. In a further preferred method of the invention, the therapeutic agent is the gene encoding the Cystic Fibrosis Trans-membrane Conductance Regulator.
- A further aspect of the invention provides the use of moveable magnetic means in the manufacture of a system for targeting particles comprising a therapeutic agent to a target cell. Preferably the magnetic means are in motion, preferably still in constant motion.
- In a preferred use according to the invention the magnetic means are used to apply a magnetic force to the particles so as to tend to move the particles towards or away from the magnetic means and at the same time moving the magnetic means.
- In a further preferred use according to the invention the magnetic means are used to apply a magnetic force to the particles so as to tend to move the particles in a first direction towards or away from the magnetic means and at the same time moving the magnetic means relative to the particles in a second direction at an angle to the first direction.
- Where the use is in vivo, the magnetic means may be moved external to the body. The movement of the magnetic means may be controlled by a motor or a magnet. The movement of the magnetic means may be remotely controlled.
- Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, means “including but not limited to”, and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.
- Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
- Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.
- The invention will be described by way of example only with reference to the following figures:
-
FIG. 1 is a schematic representation of the magnet array drive system and sample holder for in vitro cell culture and Air/Liquid Interface (tissue) studies; -
FIG. 2 shows GFP expression in HEK293T cells transfected with 150 nm magnetic nanoparticles coated with pEGFPC 1 DNA in response to magnetic field; -
FIG. 3 is a histogram showing luciferase activity in HEK293 T cells transfected with 150 nm magnetic nanoparticles coated with pCIKLux luciferase reporter; and -
FIG. 4 is a histogram showing luciferase activity in NC1-H292 human lung epithelial cells transfected with OzBiosciences Polymag® particles coated with pCIKLux luciferase reporter construct in response to static and oscillating magnetic fields. All transfections were performed in 96 well tissue culture plates using 0.1 μg DNA/well. Genejuice (GJ) and Lipofectamine 2000 (LF2000) transfections were carried out according to the manufacturer's recommended protocol. Data shown as mean±SEM (n=6 for all groups). Magnet diameter=6 mm. - The reporter genes Green Fluorescent Protein (GFP) and luciferase were attached to commercially available magnetic nanoparticles. The particles generally consisted of a magnetic core (magnetite—Fe3O4 and/or its oxidation product maghemite—γFe2O3) with a polymer coating, such as dextran, PVA or silica, and ranged in size from ˜10 nm to ˜1 μm. Magnetite is a naturally occurring iron oxide and is found in many organs in the human body. In addition magnetite is FDA-approved for MRI contrast enhancement and thus is suitable for clinical trials.
- Magnetic nano-particles coated with 1800 branched polyethyleneimine (PEI) were incubated with DNA in order to bind the reporter genes to the particles. The gene/particle complex was then introduced into mono-layer cultures of HEK293T kidney cells within the incubator. Culture dishes were positioned on a custom-built holder above the magnet array, housed within the incubator.
- The reporter gene/particle complex is targeted to cells via a high gradient rare earth (NdFeb) magnet which are focused over the target site. These magnets produce a translational force on the particles due to the high field strength/gradient product according to the equation:
-
- where x2 is the volume magnetic susceptibility of the magnetic particle, x1 is the volume magnetic susceptibility of the surrounding medium, μo is the magnetic permeability of free space, B is the magnetic flux density in Telsa (T) (Pankhurst et al. 2003). This translational force ‘pulls’ the particles towards the magnet.
- The particles are delivered using a high precision oscillating horizontal drive system which is controlled by a computer and custom designed control software. The amplitude of the array's drive system can vary between a few nanometers to millimeters and the frequency can vary from static up to 100's of Hz depending upon the parameters for the target.
- HEK293T cells were seeded in 96 well plates at 5×103 cells/well. The cells were transfected with 5 ug/well of 150 nm dextran/magnetite composite nanoparticles coated with PEI, loaded with pCIKlux DNA (binding capacity approx 0.2 ug DNA/ug particles). The cells were exposed to magnetic fields as shown for 24 hr post transfection, using a stack of 3×NdFeB 4 mm magnets per well. The cells exposed to moving field were exposed for 2 hrs at 2 Hz using a 200 μm displacement and then the magnets left in place for 22 hrs in static position.
- Data shown in
FIGS. 2 and 3 as average +/−SEM (n=12 for each group).
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/535,267 US20120288505A1 (en) | 2005-04-22 | 2012-06-27 | Gene delivery |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0508110.4 | 2005-04-22 | ||
GBGB0508110.4A GB0508110D0 (en) | 2005-04-22 | 2005-04-22 | Gene delivery |
PCT/GB2006/001477 WO2006111770A2 (en) | 2005-04-22 | 2006-04-21 | Gene delivery |
US91219808A | 2008-06-12 | 2008-06-12 | |
US13/535,267 US20120288505A1 (en) | 2005-04-22 | 2012-06-27 | Gene delivery |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2006/001477 Continuation WO2006111770A2 (en) | 2005-04-22 | 2006-04-21 | Gene delivery |
US91219808A Continuation | 2005-04-22 | 2008-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120288505A1 true US20120288505A1 (en) | 2012-11-15 |
Family
ID=34639915
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/912,198 Expired - Fee Related US8232102B2 (en) | 2005-04-22 | 2006-04-21 | Gene delivery |
US13/535,267 Abandoned US20120288505A1 (en) | 2005-04-22 | 2012-06-27 | Gene delivery |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/912,198 Expired - Fee Related US8232102B2 (en) | 2005-04-22 | 2006-04-21 | Gene delivery |
Country Status (11)
Country | Link |
---|---|
US (2) | US8232102B2 (en) |
EP (1) | EP1885450B1 (en) |
JP (1) | JP5167119B2 (en) |
CN (1) | CN101193681A (en) |
AT (1) | ATE470477T1 (en) |
AU (1) | AU2006238697B2 (en) |
CA (1) | CA2605533A1 (en) |
DE (1) | DE602006014821D1 (en) |
ES (1) | ES2345505T3 (en) |
GB (1) | GB0508110D0 (en) |
WO (1) | WO2006111770A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020171783A1 (en) * | 2019-02-20 | 2020-08-27 | Sabanci Üniversitesi | Rotary magnetic actuation system |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20030376A1 (en) | 2003-07-31 | 2005-02-01 | Univ Roma | PROCEDURE FOR THE ISOLATION AND EXPANSION OF CARDIOC STAMIN CELLS FROM BIOPSIA. |
US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
EP2023813A4 (en) * | 2006-05-15 | 2013-03-13 | Dmitri B Kirpotin | Magnetic microparticles comprising organic substances |
GB0717582D0 (en) * | 2007-09-10 | 2007-10-17 | Univ Keele | Magnetic transfection device |
EP2338520A1 (en) | 2009-12-21 | 2011-06-29 | Ludwig Maximilians Universität | Conjugate with targeting ligand and use of same |
US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
US9669200B2 (en) | 2010-08-06 | 2017-06-06 | Boston Scientific Scimed, Inc. | Systems and methods for the treatment of pelvic disorders including magnetic particulates |
US9180172B2 (en) | 2010-12-15 | 2015-11-10 | Ams Research Corporation | Treatment of Peyronies disease |
US8979797B2 (en) | 2010-12-16 | 2015-03-17 | Ams Research Corporation | High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics |
CN102172410B (en) * | 2011-01-14 | 2013-08-07 | 华南理工大学 | Construction method of targeted nano particle transmission system for cancer diagnosis and treatment |
EP2861238A4 (en) | 2012-06-05 | 2016-03-16 | Capricor Inc | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
CN104349794B (en) * | 2012-06-08 | 2019-01-04 | 埃泽瑞斯公司 | The lung of mRNA delivers |
WO2014028493A2 (en) | 2012-08-13 | 2014-02-20 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
US9951374B2 (en) | 2013-02-19 | 2018-04-24 | Wisconsin Alumni Research Foundation | Enhanced throughput mineral coatings for optimization of stem cell behavior |
CA2962444C (en) | 2014-10-03 | 2023-09-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
WO2017123662A1 (en) | 2016-01-11 | 2017-07-20 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
WO2018057542A1 (en) | 2016-09-20 | 2018-03-29 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
AU2018255346B2 (en) | 2017-04-19 | 2024-05-02 | Capricor, Inc. | Methods and compositions for treating skeletal muscular dystrophy |
WO2019126068A1 (en) | 2017-12-20 | 2019-06-27 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
EP4292660A1 (en) * | 2022-06-13 | 2023-12-20 | Fortis GmbH | System for administration of an active agent |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4652257A (en) * | 1985-03-21 | 1987-03-24 | The United States Of America As Represented By The Secretary Of The Navy | Magnetically-localizable, polymerized lipid vesicles and method of disrupting same |
US6447499B2 (en) * | 1995-07-28 | 2002-09-10 | James R. Gray | Use of a polarized field to modify the efficacy of a bioactive agent |
US6203487B1 (en) | 1997-12-31 | 2001-03-20 | Thomas Jefferson University | Use of magnetic particles in the focal delivery of cells |
WO2002000870A2 (en) * | 2000-06-26 | 2002-01-03 | Christian Plank | Method for transfecting cells using a magnetic field |
US6997863B2 (en) * | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
WO2003068953A1 (en) * | 2002-02-12 | 2003-08-21 | The Mollennium Laboratories | Molecule vibrator |
WO2004034876A2 (en) * | 2002-10-15 | 2004-04-29 | Ferx Incorporated | Magnetically guided particles for radiative therapies |
EP1553176A4 (en) | 2002-10-16 | 2008-10-01 | Universal Bio Research Co Ltd | Apparatus for introducing biological material, method of introducing biological material and magnetic support for introducing biological material |
US8001977B2 (en) | 2005-04-08 | 2011-08-23 | Nanobiomagnetics, Inc. | Device for moving magnetic nanoparticles through tissue |
WO2005025508A2 (en) * | 2003-09-12 | 2005-03-24 | Bankruptcy Estate Of Ferx, Inc. | Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents |
-
2005
- 2005-04-22 GB GBGB0508110.4A patent/GB0508110D0/en not_active Ceased
-
2006
- 2006-04-21 EP EP06726867A patent/EP1885450B1/en not_active Not-in-force
- 2006-04-21 ES ES06726867T patent/ES2345505T3/en active Active
- 2006-04-21 DE DE602006014821T patent/DE602006014821D1/en active Active
- 2006-04-21 JP JP2008507169A patent/JP5167119B2/en not_active Expired - Fee Related
- 2006-04-21 WO PCT/GB2006/001477 patent/WO2006111770A2/en active Application Filing
- 2006-04-21 CN CNA2006800208906A patent/CN101193681A/en active Pending
- 2006-04-21 CA CA002605533A patent/CA2605533A1/en not_active Abandoned
- 2006-04-21 AU AU2006238697A patent/AU2006238697B2/en not_active Ceased
- 2006-04-21 US US11/912,198 patent/US8232102B2/en not_active Expired - Fee Related
- 2006-04-21 AT AT06726867T patent/ATE470477T1/en not_active IP Right Cessation
-
2012
- 2012-06-27 US US13/535,267 patent/US20120288505A1/en not_active Abandoned
Non-Patent Citations (12)
Title |
---|
Bennett, J., 2003, Gene Therapy, Vol. 10, p. 977-982. * |
Castro et al., 2001, Histl. Histopathol., Vol. 16, p. 1225-1238. * |
Chattopadhyay et al., 2004, Virus Research, Vol. 99, p. 139-145. * |
Gorecki, D., 2001, Expert Opin. Emerging Drugs, 6(2): 187-198. * |
Jin et al., 2007, US 20070196281 A1, effective filing date, 12-31-03. * |
Kodama et al., 2006, Current Medicinal Chemistry, Vol. 13, p. 2155-2161. * |
Lebedeva et al., 2003, Seminars in Cancer Biology, Vol. 12, p. 169-178. * |
Lowenstein et al., 2002, Current Opinion in Molecular Therapeutics, Vol. 4, No. 4, p. 359-371. * |
Skolnick et al., 2000, Trends in Biotech, Vol. 18, p. 34-39. * |
Smallwood et al., 2002,, Virology, Vol. 304, p. 135-145. * |
Thomas et al., 2003, Nature Reviews/ Genetics, Vol. 4, p. 346-358. * |
Tomasinsig et al., 2005, Current Protein and Peptide Science, Vol. 6, p. 23-34. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020171783A1 (en) * | 2019-02-20 | 2020-08-27 | Sabanci Üniversitesi | Rotary magnetic actuation system |
Also Published As
Publication number | Publication date |
---|---|
WO2006111770A2 (en) | 2006-10-26 |
GB0508110D0 (en) | 2005-06-01 |
US8232102B2 (en) | 2012-07-31 |
AU2006238697B2 (en) | 2011-12-08 |
CN101193681A (en) | 2008-06-04 |
US20080286361A1 (en) | 2008-11-20 |
EP1885450A2 (en) | 2008-02-13 |
WO2006111770A3 (en) | 2007-05-18 |
ES2345505T3 (en) | 2010-09-24 |
AU2006238697A1 (en) | 2006-10-26 |
JP2008536907A (en) | 2008-09-11 |
JP5167119B2 (en) | 2013-03-21 |
ATE470477T1 (en) | 2010-06-15 |
DE602006014821D1 (en) | 2010-07-22 |
EP1885450B1 (en) | 2010-06-09 |
CA2605533A1 (en) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8232102B2 (en) | Gene delivery | |
Aslam et al. | Current and future perspectives of multifunctional magnetic nanoparticles based controlled drug delivery systems | |
Arsianti et al. | Assembly of polyethylenimine-based magnetic iron oxide vectors: insights into gene delivery | |
Gandra et al. | Virus‐mimetic cytoplasm‐cleavable magnetic/silica nanoclusters for enhanced gene delivery to mesenchymal stem cells | |
Majidi et al. | Magnetic nanoparticles: Applications in gene delivery and gene therapy | |
McBain et al. | Magnetic nanoparticles for gene and drug delivery | |
Mok et al. | Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeutics | |
Prijic et al. | Surface modified magnetic nanoparticles for immuno-gene therapy of murine mammary adenocarcinoma | |
Dobson | Magnetic micro-and nano-particle-based targeting for drug and gene delivery | |
Prijic et al. | Magnetic nanoparticles as targeted delivery systems in oncology | |
Kumar et al. | Multifunctional magnetic nanoparticles for targeted delivery | |
US9095610B2 (en) | Uniform field magnetization and targeting of therapeutic formulations | |
I Schwerdt et al. | Magnetic field-assisted gene delivery: achievements and therapeutic potential | |
Prosen et al. | Magnetofection: a reproducible method for gene delivery to melanoma cells | |
Samal et al. | Multilayered magnetic gelatin membrane scaffolds | |
Miao et al. | Antitumor effect of TRAIL on oral squamous cell carcinoma using magnetic nanoparticle-mediated gene expression | |
Sizikov et al. | Nonviral locally injected magnetic vectors for in vivo gene delivery: A review of studies on magnetofection | |
Wang et al. | Magnetic multi-walled carbon nanotubes for tumor theranostics | |
Bhattarai et al. | N-hexanoyl chitosan-stabilized magnetic nanoparticles: enhancement of adenoviral-mediated gene expression both in vitro and in vivo | |
Oral et al. | Effect of varying magnetic fields on targeted gene delivery of nucleic acid-based molecules | |
JP2010538607A (en) | Magnetic delivery device | |
Ramanujan | Magnetic particles for biomedical applications | |
Bertram | MATra-Magnet Assisted Transfection: combining nanotechnology and magnetic forces to improve intracellular delivery of nucleic acids | |
Cruz-Acuña et al. | From oleic acid-capped iron oxide nanoparticles to polyethyleneimine-coated single-particle magnetofectins | |
Uthaman et al. | 9—Fabrication and development of magnetic particles for gene therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KEELE UNIVERSITY, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DOBSON, JON;BATICH, CHRISTOPHER D.;SIGNING DATES FROM 20071210 TO 20071211;REEL/FRAME:028639/0231 Owner name: NANOTHERICS LTD., UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KEELE UNIVERSITY;UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.;SIGNING DATES FROM 20100825 TO 20100826;REEL/FRAME:028639/0207 Owner name: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., F Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DOBSON, JON;BATICH, CHRISTOPHER D.;SIGNING DATES FROM 20071210 TO 20071211;REEL/FRAME:028639/0231 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |